In addition, preclinical data suggest that GLP-1 agonists may have anti-inflammatory, immunoregulatory, and chondroprotective effects, potentially benefiting OA patients. According to Wright, further analysis is necessary to understand if these medications can truly impact OA patients beyond pain management
Related Stories Medically tailored grocery deliveries improve blood sugar control among diabetes patients Semaglutide and tirzepatide linked to fewer alcohol-related hospital visits New home test uses thigh length to detect type 2 diabetes or prediabetes During a median follow-up of approximately one year, 1,104 participants had an incident diabetes event and 57 experienced cardiovascular disease events
This low-maintenance solution to weight loss is very accessible
MT2 Vial is a synthetic cyclic heptapeptide and an analog of the natural -melanocyte-stimulating hormone (-MSH)
u c tnh to, minh mn
(Wegovy, Ozempic, Zepbound, or Foundayo only) Pregnancy and breastfeeding: Speak with your provider if you are or plan to be pregnant or breastfeeding, as these GLP-1 agonists should only be used during pregnancy or breastfeeding if the potential benefit outweighs potential risk to the fetus or breastfed infant